Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bristol Myers Squibb

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY NKTR
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY EXEL
Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
From Bristol Myers Squibb
Via Business Wire
Tickers BMY IPSC
Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.